CATCH: A Proof of Concept Study to Evaluate the Administration of CN-105 in Patients with Acute Supratentorial Intracerebral Hemorrhage

HUMAN CLINICAL TRIAL - CONFIDENTIAL This is a multicenter, open-label phase 2a trial of CN-105 in patients with supratentorial intracerebral hemorrhage (ICH). Patients will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants (approximately 60) will receive CN-105 administered intravenously (IV) for a 30-minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days). Participants will be monitored daily throughout the Treatment phase of the study (up to a maximum of 5 days) and will receive standard-of-care treatment for the duration of the study. Additional protocol assessments will be required during the Treatment phase as outlined in Section 7.5.10. After discharge from the hospital, participants will enter a 3-month Followup phase, with a clinic visit at 30 days and a follow-up telephone interview with telephone-validated mRS at 90 days after first dose of study agent. The study is not powered to test any specific hypothesis in regard to safety and will instead use descriptive methods to describe the experience of the study cohort with respect to adverse and serious adverse events (SAEs), as well as the occurrence of several prespecified events of interest. The secondary objective of this study will be met by comparing the modified Rankin score (mRS) at 30 days between participants treated on this protocol and matched controls randomly selected from Duke University Hospital’s historical cohort and a 3000 subject cohort from the ERICH study of supratentorial ICH participants. Controls will be matched to treated participants by age (in 5-year groups), sex, and ICH Score. The mRS at 30 days will be compared between treated and control participants using the Wilcoxon rank sum test. Exploratory analyses include comparison of treated and control participants for radiographic cerebral edema and hematoma volume and expansion and biological markers of inflammation.